Study Stopped
Closed at the request of the IRBO
Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies
Apheresis Procedures to Obtain Plasma or Leukocytes for In Vitro Studies
2 other identifiers
observational
205
1 country
1
Brief Summary
This study will collect blood plasma and white blood cells for laboratory research using a procedure called apheresis. Apheresis is a method of collecting larger quantities of certain blood components than can safely be collected through a simple blood draw. Patients 7 years of age and older with a parasitic infection or condition associated with a parasitic infection (i.e., elevated levels of IgE antibodies or of a type of white cell called eosinophils) who are currently enrolled in a NIH clinical research protocol may be eligible for this study. Relatives of patients and normal healthy volunteers will also be enrolled. Candidates will have a medical history, physical examination and blood tests. Individuals weighing less than 25 kilograms (55 pounds) may not participate. Participants will undergo one of the following two apheresis procedures:
- Automated pheresis Whole blood is drawn through a needle placed in an arm vein and circulated through a cell separator machine. The plasma (liquid part of the blood) and white cells are extracted, and the red cells are re-infused into the donor through a needle in the other arm. The procedure takes 1 to 2 hours.
- Manual pheresis Whole blood is drawn through a needle placed in an arm vein and circulated through the cell separator machine. The red blood cells are separated from the rest of the blood and returned to the donor through the same needle. Usually only one needle stick is required and the procedure takes from 30 to 45 minutes. This method is used only in individuals who weigh less than 35 kg (77 pounds).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 1993
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 23, 1993
CompletedFirst Submitted
Initial submission to the registry
November 3, 1999
CompletedFirst Posted
Study publicly available on registry
November 4, 1999
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 9, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
November 9, 2021
CompletedNovember 10, 2021
November 1, 2021
28.7 years
November 3, 1999
November 9, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To obtain leukocytes,platelets, and plasma from subjects already enrolled on other NIAID/LPD protocols.
Leukocytes, platelets, and plasma will be collected.
Ongoing as this is a method to collect cells from subjects enrolled on other LPD protocols
Study Arms (1)
1
Donors first admitted to another approved clinical research protocol of the NIAID before having the apheresis procedures described in this protocol.
Eligibility Criteria
Any subject enrolled on an existing !RB-approved LPD protocol may be asked to participate and thereby undergo apheresis.
You may qualify if:
- Enrolled on another LPD protocol.
- Weight greater than or equal to 25 kg
- Willingness to participate
You may not qualify if:
- Age less than 7 years
- Weight less than 25 kg
- Cardiovascular instability
- Hct less than 30
- Inadequate venous access
- PTT or PT greater than 1.5 normal
- Pregnancy
- Women who are actively breastfeeding
- Other condition which the attending physician or Apheresis Unit staff considers a contraindication to the procedure
- For Hetastarch procedure
- Hypertension
- Evidence of fluid retention
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Related Publications (3)
Boyd A, Ribeiro JM, Nutman TB. Human CD117 (cKit)+ innate lymphoid cells have a discrete transcriptional profile at homeostasis and are expanded during filarial infection. PLoS One. 2014 Sep 25;9(9):e108649. doi: 10.1371/journal.pone.0108649. eCollection 2014.
PMID: 25255226BACKGROUNDChatterjee S, Clark CE, Lugli E, Roederer M, Nutman TB. Filarial infection modulates the immune response to Mycobacterium tuberculosis through expansion of CD4+ IL-4 memory T cells. J Immunol. 2015 Mar 15;194(6):2706-14. doi: 10.4049/jimmunol.1402718. Epub 2015 Feb 9.
PMID: 25667413BACKGROUNDSantiago Hda C, Ribeiro-Gomes FL, Bennuru S, Nutman TB. Helminth infection alters IgE responses to allergens structurally related to parasite proteins. J Immunol. 2015 Jan 1;194(1):93-100. doi: 10.4049/jimmunol.1401638. Epub 2014 Nov 17.
PMID: 25404363BACKGROUND
Related Links
Biospecimen
Leukocytes, platelets and plasma will be collected. Since this protocol only allows for apheresis to be performed on participants enrolled on another LPD protocol, any biological samples collected will be covered by the other, individual protocol on which the participant is enrolled.
Study Officials
- PRINCIPAL INVESTIGATOR
Thomas B Nutman, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- NIH
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 1999
First Posted
November 4, 1999
Study Start
March 23, 1993
Primary Completion
November 9, 2021
Study Completion
November 9, 2021
Last Updated
November 10, 2021
Record last verified: 2021-11